Hema Now
In this episode of Hema Now, Charles Craddock explores the changing treatment landscape for acute myeloid leukaemia. From the evolving role of transplantation and measurable residual disease-guided decisions to reduced-intensity conditioning and emerging therapies, Craddock discusses how treatment strategies are developing. He also reflects on the importance of clinical trial infrastructure in ensuring that patients can access promising new treatments, alongside his priorities for the future of acute myeloid leukaemia research.
Spotify | Apple | Amazon Music | YouTube | Download MP3
Charles Craddock is Professor of Haemato-oncology at the University of Warwick and Academic Director of the Centre for Clinical Haematol-ogy at University Hospitals Birmingham, UK. His work focuses on hae-matological malignancies, including AML, and the development of treatment strategies and clinical trials to improve patient outcomes.
Timestamps:
00:00 – Introduction
01:08 – Current AML treatment landscape
03:30 – Evolving role of transplantation
09:45 – MRD-guided transplant and treatment decisions
12:45 – Reduced-intensity conditioning and patient eligibility
18:00 – Emerging AML therapies and future treatment
19:45 – Improving AML clinical trial delivery
26:16 – Three wishes for AML research
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
